Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-31T16:23:33.879Z Has data issue: false hasContentIssue false
  • English
  • Français

Reduced suicidality with paroxetine

Published online by Cambridge University Press:  16 April 2020

JJ López-Ibor Jr
JJ López-Ibor Jr*
Affiliation:
San Carlos Hospital, Complutense University, Madrid, Spain
*
*Address for correspondence: JJ López-Ibor Jr, Nueva Zelanda 44, E-28035 Madrid, Spain
Get access

Summary

Depression is commonly associated with suicidal thoughts and behaviour. The effect of the antidepressant, paroxetine, on suicidality in depressed patients has been assessed by retrospective analysis of the worldwide database of short-term clinical trials. Data were analysed on 2963 patients treated with paroxetine. 554 placebo patients, and 1151 patients treated with an active control. The results clearly demonstrate the beneficial effect of antidepressant therapy on suicidal ideation. Paroxetine was not associated with the emergence of suicidality, which appears to be a feature of depressive disorder unrelated to antidepressant therapy.

Keywords

paroxetineSSRIsuicidal ideation
Type
Research Article
Information
European Psychiatry , Volume 8 , Issue S1: New perspectives in the pharmacological treatment of depression. Defining the ideal antidepressant. 3 November 1992, Barcelona, Spain , 1993 , pp. 17s - 19s
Copyright
Copyright © Elsevier, Paris 1993

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Arora, RCMeltzer, HY (1989) Serotonergic measures in the brains of suicide victims: 5-HT2 binding sites in the frontal cortex of suicide victims and control subjects Am J Psychiatry 146, 730–736Google ScholarPubMed
Banki, CMArato, M (1983) Amine metabolites and neuroendocrine responses related to depression and suicide J Affect Disord 5, 223–23210.1016/0165-0327(83)90045-9CrossRefGoogle ScholarPubMed
Damluji, NFFerguson, JM (1988) Paradoxical worsening of depressive symptomatology caused by antidepressants J Clin Psychopharmacol 8, 347–349CrossRefGoogle ScholarPubMed
Dunbar, GCMewett, S (1991) Evaluation of suicidal thoughts and acts with paroxetine. Paper presented at 5th World Cong Biol Psychiatry, June 9–14Google Scholar
Hagnell, OLanke, JOorsman, B (1981) Suicide rates in the Lundby study: mental illness as a risk factor for suicide Neuropsychobiology 7, 248–253CrossRefGoogle ScholarPubMed
López-Ibor, JJ JrSaiz-Ruiz, JPérez de los Cobos, JC (1985) Biological correlations of suicide and aggressivity in major depression (with melancholia): 5-hydroxyindoleacetic acid and Cortisol in cerebral spinal fluid, dexamethasone suppression test and therapeutic response to 5-hydroxytryptophan Neuropsychobiology 14, 67–74CrossRefGoogle ScholarPubMed
Mann, JJStanley, MMcBride, AMcEwan, BS (1986) Increased serotonin, and beta-adrenergic receptor binding in the frontal cortices of suicide victims Arch Gen Psychiatry 43,954–959CrossRefGoogle ScholarPubMed
Pokorny, AD (1964) Suicide rates in various psychiatric disorders J Nerv Ment Dis 139,499–506CrossRefGoogle ScholarPubMed
Roy, ADeJong, JLinnoila, M (1989) Cerebrospinal fluid monoamine metabolites and suicidal behaviour in depressed patients Arch Gen Psychiatry 46, 609–612CrossRefGoogle ScholarPubMed
Teicher, MHGlod, CCole, JO (1990) Emergence of intense suicidal preoccupation during fluoxetine treatment Am J Psychiatry 147, 207–210Google ScholarPubMed
Temoche, APugh, TFMacMahon, B (1964) Suicide rates among current and former mental institution patients J Nerv Ment Dis 138, 124–13010.1097/00005053-196402000-00005CrossRefGoogle ScholarPubMed
Träskman, LAsberg, MBertilsson, LSjöstrand, L (1981) Monoamine metabolites in CSF and suicidal behaviour Arch Gen Psychiatry 38, 631–636CrossRefGoogle Scholar
Tulloch, IFJohnson, AM (1992) The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor J Clin Psychiatry 53 (suppl), 7–12Google ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.